Nellie K. Owen

1.1k total citations
24 papers, 992 citations indexed

About

Nellie K. Owen is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Nellie K. Owen has authored 24 papers receiving a total of 992 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Radiology, Nuclear Medicine and Imaging, 11 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Nellie K. Owen's work include Radiopharmaceutical Chemistry and Applications (16 papers), Peptidase Inhibition and Analysis (9 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Nellie K. Owen is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (16 papers), Peptidase Inhibition and Analysis (9 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Nellie K. Owen collaborates with scholars based in United States and India. Nellie K. Owen's co-authors include Timothy J. Hoffman, Yubin Miao, Thomas P. Quinn, Wynn A. Volkert, Gary L. Sieckman, Hariprasad Gali, Charles J. Smith, Silvia S. Jurisson, Zhen Cheng and Jianqing Chen and has published in prestigious journals such as Journal of Medicinal Chemistry, International Journal of Cancer and Bioconjugate Chemistry.

In The Last Decade

Nellie K. Owen

24 papers receiving 965 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nellie K. Owen United States 16 766 409 285 206 124 24 992
Subhani M. Okarvi Saudi Arabia 17 851 1.1× 521 1.3× 415 1.5× 163 0.8× 189 1.5× 46 1.2k
Gary L. Sieckman United States 24 1.3k 1.6× 837 2.0× 344 1.2× 439 2.1× 341 2.8× 42 1.7k
Huiyun Zhao China 19 458 0.6× 263 0.6× 254 0.9× 124 0.6× 66 0.5× 38 894
Mohamed Altai Sweden 23 1.1k 1.4× 580 1.4× 425 1.5× 151 0.7× 70 0.6× 42 1.3k
Nhat Le United States 15 481 0.6× 189 0.5× 202 0.7× 107 0.5× 40 0.3× 27 709
Michela Aurilio Italy 15 178 0.2× 195 0.5× 219 0.8× 64 0.3× 119 1.0× 23 560
Yesen Li China 15 230 0.3× 171 0.4× 307 1.1× 111 0.5× 37 0.3× 45 766
Javad Garousi Sweden 22 790 1.0× 485 1.2× 285 1.0× 146 0.7× 27 0.2× 58 1.1k
Anzhelika Vorobyeva Sweden 20 799 1.0× 499 1.2× 330 1.2× 122 0.6× 42 0.3× 73 1.0k
Aaron M. LeBeau United States 14 116 0.2× 296 0.7× 315 1.1× 87 0.4× 21 0.2× 28 686

Countries citing papers authored by Nellie K. Owen

Since Specialization
Citations

This map shows the geographic impact of Nellie K. Owen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nellie K. Owen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nellie K. Owen more than expected).

Fields of papers citing papers by Nellie K. Owen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nellie K. Owen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nellie K. Owen. The network helps show where Nellie K. Owen may publish in the future.

Co-authorship network of co-authors of Nellie K. Owen

This figure shows the co-authorship network connecting the top 25 collaborators of Nellie K. Owen. A scholar is included among the top collaborators of Nellie K. Owen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nellie K. Owen. Nellie K. Owen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Selting, Kim A., Carol R. Reinero, Keith Branson, et al.. (2010). Targeted Combined Aerosol Chemotherapy in Dogs and Radiologic Toxicity Grading. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 24(1). 43–48. 14 indexed citations
2.
Selting, Kim A., J. Clifford Waldrep, Carol R. Reinero, et al.. (2008). Feasibility and Safety of Targeted Cisplatin Delivery to a Select Lung Lobe in Dogs via the AeroProbe ® Intracorporeal Nebulization Catheter. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 21(3). 255–268. 34 indexed citations
3.
Giblin, Michael F., Hariprasad Gali, Gary L. Sieckman, et al.. (2006). In vitro and in vivo Evaluation of 111In-labeled E. coli Heat-Stable Enterotoxin Analogs for Specific Targeting of Human Breast Cancers. Breast Cancer Research and Treatment. 98(1). 7–15. 4 indexed citations
4.
Giblin, Michael F., Gary L. Sieckman, Nellie K. Owen, et al.. (2005). Radiolabeled Escherichia coli heat-stable enterotoxin analogs for in vivo imaging of colorectal cancer. Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms. 241(1-4). 689–692. 1 indexed citations
5.
Lewis, Michael R., Jiuli Zhang, Fang Jia, et al.. (2004). Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nuclear Medicine and Biology. 31(2). 213–223. 35 indexed citations
6.
Zou, Jun, et al.. (2004). Biodistribution of filamentous phage peptide libraries in mice. Molecular Biology Reports. 31(2). 121–129. 70 indexed citations
7.
Bryan, Jeffrey N., Michael R. Lewis, Carolyn J. Henry, et al.. (2004). Development of a two‐antibody model for the evaluation of copper‐64 radioimmunotherapy. Veterinary and Comparative Oncology. 2(2). 82–90. 7 indexed citations
8.
Giblin, Michael F., Hariprasad Gali, Gary L. Sieckman, et al.. (2004). In Vitro and in Vivo Comparison of Human Escherichia coli Heat-Stable Peptide Analogues Incorporating the 111In-DOTA Group and Distinct Linker Moieties. Bioconjugate Chemistry. 15(4). 872–880. 17 indexed citations
9.
Smith, Charles J., Gary L. Sieckman, Nellie K. Owen, et al.. (2003). Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2OH)3.. PubMed. 63(14). 4082–8. 82 indexed citations
10.
Kothari, Kanchan, Raghuraman Kannan, Nagavarakishore Pillarsetty, et al.. (2003). Syntheses, in vitro and in vivo characterization of a 99mTc-(I)-tricarbonyl-benzylamino-dihydroxymethyl phosphine (NP2) chelate. Applied Radiation and Isotopes. 58(5). 543–549. 17 indexed citations
11.
Smith, Charles J., Hariprasad Gali, Gary L. Sieckman, et al.. (2003). Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nuclear Medicine and Biology. 30(2). 101–109. 90 indexed citations
12.
Hoffman, Timothy J., Hariprasad Gali, Charles J. Smith, et al.. (2003). Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.. PubMed. 44(5). 823–31. 129 indexed citations
13.
Gali, Hariprasad, Gary L. Sieckman, Timothy J. Hoffman, et al.. (2002). Chemical Synthesis of Escherichia Coli STh Analogues by Regioselective Disulfide Bond Formation:  Biological Evaluation of an 111In-DOTA−Phe19-STh Analogue for Specific Targeting of Human Colon Cancers. Bioconjugate Chemistry. 13(2). 224–231. 25 indexed citations
14.
Miao, Yubin, et al.. (2002). In vivo evaluation of 188Re‐labeled alpha‐melanocyte stimulating hormone peptide analogs for melanoma therapy. International Journal of Cancer. 101(5). 480–487. 83 indexed citations
15.
Kothari, Kanchan, Hariprasad Gali, Kandikere Ramaiah Prabhu, et al.. (2002). Synthesis and characterization of 99mTc- and 188Re-complexes with a diamido-dihydroxymethylenephosphine-based bifunctional chelating agent (N2P2-BFCA). Nuclear Medicine and Biology. 29(1). 83–89. 16 indexed citations
16.
Cheng, Zhen, Jianqing Chen, Yubin Miao, et al.. (2002). Modification of the Structure of a Metallopeptide:  Synthesis and Biological Evaluation of 111In-Labeled DOTA-Conjugated Rhenium-Cyclized α-MSH Analogues. Journal of Medicinal Chemistry. 45(14). 3048–3056. 70 indexed citations
17.
Gali, Hariprasad, Gary L. Sieckman, Timothy J. Hoffman, et al.. (2001). In vitro and in vivo characterization of a new receptor specific indium‐111 labeled DOTA‐ST conjugate for targeting guanylin receptors in human colon cancer cells. Journal of Labelled Compounds and Radiopharmaceuticals. 44(S1). 2 indexed citations
18.
Chen, Jianqing, Zhen Cheng, Nellie K. Owen, et al.. (2001). Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties.. PubMed. 42(12). 1847–55. 79 indexed citations
19.
Gali, Hariprasad, Gary L. Sieckman, Timothy J. Hoffman, et al.. (2001). In Vivo evaluation of an 111 In-labeled ST-peptide analog for specific-targeting of human colon cancers. Nuclear Medicine and Biology. 28(8). 903–909. 11 indexed citations
20.
Gali, Hariprasad, Timothy J. Hoffman, Gary L. Sieckman, et al.. (2001). Synthesis, Characterization, and Labeling with 99mTc/188Re of Peptide Conjugates Containing a Dithia-bisphosphine Chelating Agent. Bioconjugate Chemistry. 12(3). 354–363. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026